FREE SHIPPING + 30% Discount Special. Buy Now ยป
Oprava Cream
Pain Relief
Safe & Fast-Acting
Oprava is a specially patented formula in a base containing Omega Oils, Vitamins A and E, to provide antioxidant benefits.
The main ingredients in Oprava have been shown in clinical trials to reduce inflammation.
ABOUT OPRAVA
The product is unique because the omega oils act as a vehicle to enhance the delivery of all other ingredients. Water based compounds cannot penetrate the skin barrier for cellular delivery, but the omega oils do because they are lipophilic.
In vitro studies in Wales have demonstrated enhanced transcutaneous absorption of ibuprofen in the presence of a fatty acid such as omega 3. The latter acts as a "carrier protein" to cross a pigskin barrier Int J Pharm.2003 Aug 11:261(102) 165-9.
In short, Oprava's patent-protected compound, comprising omega fatty acids, is a topical analgesic that not only delivers inflammation-fighting omega fatty acids trans-dermally to the source of the pain, but also utilizes omega fatty acids to increase absorption and absorption speed. Further, per Cardiff University's findings, increased concentrations of both methyl salicylate and omega-3 fatty acids are correlated with greater absorption concentration of both inflammation and pain-fighting ingredients in the tissues. It is believed this result would work the same in Oprava, increasing pain and inflammation-fighting effectiveness as concentrations of omega fatty acids are increased in the compound.
Also, recent studies from Harvard (Dr. Serhan's group) have demonstrated a synergism between omega-3 fatty acids and aspirin. They form a very potent newly identified antiinflammatory compound, resolvin-1. This, of course, is Oprava's formula.
| EFFECTS OF OMEGA-3 FATTY ACIDS | CONSEQUENCE |
| Decreased monocyte production of IL-1, IL-2, TNF | Immune system down-regulation |
| Decreased endothelial permeability | Anti-inflammation |
| Increase in endothelial-dependent vasodilatation | Anti-aggregation |
| Eicosanoid-independent inhibition of platelet function | Vasodilation |
| Decreased endothelial PDGF | Anti-adhesion |
INDICATIONS:
OPRAVA SPECIFIC USES AND MORE**
Chronic pain syndromes and fibromyalgia
Osteoarthritis
Periarthritis
Myalgia Syndromes/ Myositis
Rheumatoid Arthritis
Tendonitis/bursitis
Some inflammatory arthropathies
Physical therapy, with phoresis and massage
Muscle cramps
**The topical use of this compound avoids the gastrointestinal and other side effects of commonly used anti-inflammatory oral agents.
BENEFITS:
- Fast-acting Omega-3 fatty acids
- May act as an adjunct to other conventional medicines
- Few if any side-effects
- Shown in two open-label effectiveness pilot trials to be over 90% effective:
EFFECTIVENESS TRIALS*:
Open label Studies with Oprava cream for the treatment of rheumatic disease.
STUDY 1: Case-series Intervention Study: Cases were 94 out-patient subjects seen over 6 months in a rheumatology practice. Subjects had Osteoarthritis, Rheumatoid Arthritis, Fibromyalgia, Bursitis, and/or Tennis Elbow. Methods: Patients were given Oprava and after two weeks of use then reported effects on a visual analog scale as 1-poor, 2-fair, 3-good, or 4-excellent. Results: Followup was obtained for 91 (96.8%) of patients. Mean (SE) score for patients with Osteoarthritis was 3.32 (0.77), Rheumatoid Arthritis 3.24 (0.66), Fibromyalgia 3.17 (0.83), Bursitis 3.06 (0.96) and Tennis Elbow 3.06 (1.00). See Figure 1.
STUDY 2: Case Series Intervention Study: 170 out-patients treated over 4 weeks in a primary care practice in San Diego for Osteoarthritis, Bursitis, Tendonitis, Sprains, Neuropathies, and other diseases. Methods: Patients were given Oprava to take home and use for two weeks. The physician reported whether a therapeutic response was evident or not. Results: 98.8% of patients were responders and only 1.2% did not show a response to Oprava. See Table 1.
Table 1: Patient response to Oprava
| CLINCIAL ENTITY | RESPONDERS TO OPRAVA | NON-RESPONDERS TO OPRAVA |
| Osteoarthritis | 47 | 1 |
| Bursitis | 12 | 0 |
| Tendonitis | 11 | 0 |
| Sprains | 10 | 0 |
| Neuropathies | 24 | 0 |
| Other | 64 | 1 |
*In-house clinical data of Biological MD Solutions.
STUDY 3: Placebo Study - 12 patients from the same rheumatology practice with similar diseases as in the case-series study were enrolled. 6 patients had previously reported good results with Oprava for 4 weeks, and 6 were new patients. Methods: Patients were given a placebo without their knowledge which looked and smelled like Oprava, and then after two weeks, patients reported effects on a visual analog scale as 1-poor, 2-fair, 3-good, or 4-excellent. Results: Patients reported a mean response of 1.25, slightly better than poor. See Figure 2.
